Halozyme Shares Dip as Wells Fargo Flags Review in Patent Case

June 3, 2025, 1:40 PM UTC

Halozyme Therapeutics shares slip as much as 2.9% after Wells Fargo said the Patent Trial and Appeal Board has instituted a patent grant review (PGR) against the company amid an ongoing infringement lawsuit with Merck & Co.

  • The institution of the PGR likely reduces the probability of Halozyme prevailing in the patent infringement case, analyst Mohit Bansal writes in a note to clients
    • Halozyme winning the infringement suit is a “bull case” that is often noted as a potential source of upside
    • “Institution of MRK’s PGR lowers the probability of this bull case”
    • Notes HALO has downplayed the significance of ...



Learn more about Bloomberg Law or Log In to keep reading:

See Breaking News in Context

Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.

Already a subscriber?

Log in to keep reading or access research tools and resources.